(TCAD) A Phase 2 Multi-center, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients with Mild to Moderate Alzheimer’s Disease

The PI of this project was:

This project was funded by: Toyama Chemical

The term of this project was: August 2014 to April 2016

The number of subjects scanned during this project was: 12